Javadin is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 15, 2042. Details of Javadin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12440474 | Stable Pharmaceutical Compositions Of Clonidine |
Jul, 2042
(16 years from now) | Active |
| US12233049 | Stable Pharmaceutical Compositions Of Clonidine |
Jul, 2042
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Javadin's patents.
Latest Legal Activities on Javadin's Patents
Given below is the list of recent legal activities going on the following patents of Javadin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Application Is Considered Ready for Issue | 16 Sep, 2025 | US12440474 |
| Dispatch to FDC | 16 Sep, 2025 | US12440474 |
| Issue Fee Payment Received | 15 Sep, 2025 | US12440474 |
| Miscellaneous Incoming Letter | 15 Sep, 2025 | US12440474 |
| Issue Fee Payment Verified | 15 Sep, 2025 | US12440474 |
| Email Notification | 02 Sep, 2025 | US12440474 |
| Mail Examiner Interview Summary (PTOL - 413) | 02 Sep, 2025 | US12440474 |
| Interview Summary Record | 28 Aug, 2025 | US12440474 |
| Interview Summary - Applicant Initiated - Telephonic | 28 Aug, 2025 | US12440474 |
| Electronic request for Examiner Interview | 22 Aug, 2025 | US12440474 |
US patents provide insights into the exclusivity only within the United States, but
Javadin is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Javadin's family patents as well as insights into
ongoing legal events
on those patents.
Javadin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Javadin's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 15, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Javadin Generic API suppliers:
Clonidine Hydrochloride is the generic name for the brand Javadin. 35 different companies have already filed for the generic of Javadin, with Actavis Elizabeth having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Javadin's generic
Alternative Brands for Javadin
There are several other brand drugs using the same active ingredient (Clonidine Hydrochloride) as Javadin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clonidine Hydrochloride, Javadin's active ingredient. Check the complete list of approved generic manufacturers for Javadin
About Javadin
Javadin is a drug owned by Azurity Pharmaceuticals Inc. Javadin uses Clonidine Hydrochloride as an active ingredient. Javadin was launched by Azurity in 2025.
Approval Date:
Javadin was approved by FDA for market use on 23 October, 2025.
Active Ingredient:
Javadin uses Clonidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Clonidine Hydrochloride ingredient
Dosage:
Javadin is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.02MG/ML | SOLUTION | Prescription | ORAL |